Form 4: NextCure CFO Steven P. Cobourn Acquires 117,375 Stock Options

NextCure's Chief Financial Officer, Steven P. Cobourn, has been granted 117,375 employee stock options.

Summary

• Steven P. Cobourn, the Chief Financial Officer of NextCure, Inc., has reported a transaction involving the acquisition of 117,375 employee stock options.
• The options were granted on January 31, 2025, with an exercise price of $0.8048 per share.
• The options vest over time, with one-fourth vesting on January 31, 2026, and the remainder vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of one-fourth after one year and the remainder over three years is a typical vesting schedule for stock options.
• The exercise price of $0.8048 is a common practice for stock options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing shareholder value.

Key Dates

Keywords

stock options, insider trading, executive compensation, NextCure, NXTC, Steven P. Cobourn, CFO